Osmolarity: A hidden factor in Nanotoxicology  by unknown
LETTER TO THE EDITOR Open Access
Osmolarity: A hidden factor in
Nanotoxicology
Saeid Moayyedi1, Omid Mashinchian2 and Rassoul Dinarvand3*
Abstract
In the field of drug delivery, long circulating nanocarriers in the blood have many advantages such as
targeted drug delivery and sustained release. Based on our current knowledge, evaluation of the effect of
long circulating nanocarriers in the blood stream on osmolarity of plasma has not been reported before. In
this study, osmotic pressure developed by some commercially available nanocarriers was estimated based on
Van't Hoff equation. It is noteworthy that theoretically, nanocarriers do not have any significant effect on
osmolarity of plasma. However, it is worth being evaluated experimentally in order to be taken into account
in future studies.
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Letters to the editor
An osmosis phenomenon is the net movement of
solvent (usually water) through a semipermeable
membrane from a region of high water concentration
(hypoosmolar solution) to a lower water concentration
(hyperosmolar solution). Adding a solute to pure
water decreases water concentration in the solution.
In such conditons, water molecules can diffuse from
a region of low solute concentration to one with a
high solute concentration [1]. The effect of diverse
solutes (i.e., molecules or ions) on osmolarity is
depended on the number of dissolved particles in a
solution, and is not correlated to their mass. Conse-
quently, in an equal mass ratio, macromolecules (e.g.,
proteins, nucleic acids, polysaccharides) have much
less influence on the osmolarity of a solution in com-
parison with their monomeric components. For ex-
ample, a gram of a polysaccharide comprised of 1,000
glucose units and a milligram of glucose have the
identical effect on osmolarity. In order to prevent of
an enormous increase in osmolarity inside the storage
cell (e.g., hepatocyte), the fuel is stored in the form of
polysaccharide (i.e., starch or glycogen) rather than
glucose or other simple sugars by the cells [2].
Similarly, increasing osmolarity of plasma leads to
net reabsorption of fluid from interstitial fluid into
the capillaries rather than net filtration. On the other
hand, increasing osmolarity of plasma leads to anti-
diuretic hormone secretion. Osmolarity of plasma is
approximately 300 mOsm/L. Change as small as 1 %
in osmolarity of plasma leads to increasing antidiure-
tic hormone secretion significantly. This hormone de-
creases the excreted volume of fluid by the kidneys.
Ultimately, Due to increased blood volume, arterial
pressure increases [1, 3].
In the field of drug delivery, long circulating nano-
carriers in the blood have many advantages such as
targeted drug delivery and sustained release [4–6].
Until now, numerous studies have been performed in
the Nanotoxicology [7, 8]. Nevertheless, evaluation of
the effect of long circulating nanocarriers in the
blood stream on osmolarity of plasma has not been
reported before.
For this reason, osmotic pressure developed by
some commercially available nanocarriers per 1 L of
plasma estimated based on Van't Hoff equation. Data
shown in Table 1 illustrates that theoretically, nano-
carriers do not have any significant effect on osmolar-
ity of plasma. However, it is worth being evaluated
experimentally in order to be taken into account in
future studies.
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Table 1 Estimation of osmotic pressure developed by some
commercially available nanocarriers per 1 L of plasma
Trade name Osmotic pressure (mm Hg) Osmolarity (mOsm/L)
Doxil 7.0 × 10−5 4.0 × 10−6
Abraxane 2.0 × 10−2 1.0 × 10−3
AmBisome 3.2 × 10−4 1.7 × 10−5
Marqibo 3.2 × 10−5 1.7 × 10−6
DepoCyt 3.0 × 10−5 2.3 × 10−6
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